Screener
Avalo Therapeutics AVTX Total Revenue
Discontinued — last reported Q4 '25
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Avalo Therapeutics’s 10-K, filed March 23, 2026.
- Filed
- Mar 23, 2026, 7:02 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001534120-26-000011
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Revenues: | ||
| Product revenue, net | $59 | $441 |
| Total revenues, net | 59 | 441 |
| Operating expenses: | ||
| Cost of product sales | — | (366) |
| Research and development | 50,084 | 24,437 |
| Acquired in-process research and development | — | 27,641 |
| General and administrative | 22,900 | 17,241 |
Item 16. Form 10-K Summary
FAQ
- What is Avalo Therapeutics's total revenue?
- Avalo Therapeutics (AVTX) reported total revenue of $59K in Q4 2025.
- How has Avalo Therapeutics's total revenue changed year-over-year?
- Avalo Therapeutics's total revenue decreased by 69.3% year-over-year, from $192K to $59K.
- What is the long-term trend for Avalo Therapeutics's total revenue?
- Over 3 years (2021 to 2024), Avalo Therapeutics's total revenue has grown at a -56.6% compound annual growth rate (CAGR), from $5.4M to $441K.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Avalo Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude